Transverse myelitis
disease diseaseOn this page
Also known as Myelitis, TransverseTransverse Myelopathy SyndromeTransverse Myelopathy Syndromes
Summary
Transverse myelitis (MONDO:0021553) is a disease and 22 clinical trials. Top therapeutic interventions include dalfampridine, mitoxantrone, and interferon beta. A subtype of myelitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 22
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | transverse myelitis |
| Mondo ID | MONDO:0021553 |
| DOID | DOID:0080743 |
| ICD-11 | 1328350091 |
| SNOMED CT | 16631009 |
| UMLS | C0026976 |
| MedGen | 6488 |
| MedDRA | 10028527 |
| Is cancer (heuristic) | no |
Also known as: Myelitis, Transverse · transverse myelitis · Transverse Myelopathy Syndrome · Transverse myelopathy syndrome · transverse myelopathy syndrome · Transverse Myelopathy Syndromes
Disease family
This is a subtype of myelitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › spinal cord disorder › myelitis › transverse myelitis
Related subtypes (3): acute transverse myelitis, poliomyelitis, acute flaccid myelitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 22.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 15 |
| PHASE4 | 2 |
| PHASE3 | 2 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00179478 | PHASE4 | COMPLETED | Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis |
| NCT00304291 | PHASE4 | COMPLETED | A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) |
| NCT07100990 | PHASE3 | RECRUITING | Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) |
| NCT02398994 | PHASE3 | TERMINATED | A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis |
| NCT02166346 | PHASE2 | COMPLETED | Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) |
| NCT03887273 | PHASE1/PHASE2 | UNKNOWN | Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis |
| NCT03138421 | PHASE1 | COMPLETED | Central Pain Study for ABX-1431 |
| NCT00445367 | Not specified | ACTIVE_NOT_RECRUITING | Biobank For MS And Other Demyelinating Diseases |
| NCT00704626 | Not specified | ENROLLING_BY_INVITATION | Serum Auto-Antibodies in Neurological Diseases |
| NCT01623076 | Not specified | ACTIVE_NOT_RECRUITING | The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders |
| NCT04564495 | Not specified | ACTIVE_NOT_RECRUITING | Home Based Tele-exercise for People With Chronic Neurological Impairments |
| NCT04721717 | Not specified | RECRUITING | AIM’s Writing for Healing: A Workshop for Individuals Living With Paralysis |
| NCT05017142 | Not specified | RECRUITING | Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) |
| NCT06147258 | Not specified | RECRUITING | The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury |
| NCT06163508 | Not specified | ENROLLING_BY_INVITATION | A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells |
| NCT02144935 | Not specified | COMPLETED | Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study |
| NCT02341950 | Not specified | COMPLETED | Clinical Trial of a Serious Game for Individuals With SCI/D |
| NCT03336762 | Not specified | COMPLETED | Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis |
| NCT03942952 | Not specified | COMPLETED | PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. |
| NCT05249595 | Not specified | UNKNOWN | Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance |
| NCT05630313 | Not specified | UNKNOWN | Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil |
| NCT06055998 | Not specified | UNKNOWN | Frequency ,Etiology and Prognostic Factors of Acute Transverse Myelitis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DALFAMPRIDINE | 4 | 1 |
| MITOXANTRONE | 4 | 1 |
| INTERFERON BETA | 3 | 1 |
| ELCUBRAGISTAT | 2 | 1 |
Related Atlas pages
- Drugs: Dalfampridine, Mitoxantrone, Interferon Beta